Newsfeeds Archive - Page 2 of 4

3 minute read

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

April 16, 2:17 PM

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

ACDC

2 minute read

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

By Vandana Singh

April 16, 1:32 PM

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile.

CGEM

2 minute read

UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday

By Avi Kapoor

April 16, 10:15 AM

U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday.

ALHC

1 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

April 16, 8:07 AM

Gainers Dynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday’s pre-market session. The company’s market cap stands at…

ADXN

3 minute read

Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

By Avi Kapoor

January 30, 8:52 AM

Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter.

ADXN

2 minute read

Cullinan Oncology Announces First Patient Dosed In Phase 1 Trial Evaluating CLN-617, A Novel Fusion Protein Uniquely Harnessing Both IL-2 And IL-12 Cytokines

By Benzinga Newsdesk

December 14, 5:30 PM

Cullinan Oncology, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical

CGEM